None

None

1. patients with concomitant documented bacterial pneumonia 2. patients who are pregnant or breastfeeding. 3. known sensitivity/allergy to favipiravir 4. major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit), hiv. 5. gout/history of gout or hyperuricemia (two times above the uln) 6. having used favipiravir or participated in any other interventional drug clinical study withing 30 days prior to first dose of study drug. 7. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). 8. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. 9. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission.

1. patients with concomitant documented bacterial pneumonia 2. patients who are pregnant or breastfeeding. 3. known sensitivity/allergy to favipiravir 4. major comorbidities increasing the risk of study drug including: i. hematologic malignancy, ii. advanced (stage 4-5) chronic kidney disease or dialysis therapy, severe liver damage (child-pugh score ≥ c, ast> 5 times the upper limit), hiv. 5. gout/history of gout or hyperuricemia (two times above the uln) 6. having used favipiravir or participated in any other interventional drug clinical study withing 30 days prior to first dose of study drug. 7. the investigator believes that participating in the trial is not in the best interests of the patient, or the investigator considers unsuitable for enrollment (such as unpredictable risks or subject compliance issues). 8. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission. 9. clinical prognostic non-survival, palliative care, or in deep coma and no have response to supportive treatment within three hours of admission.